Can we avoid dose escalation for intermediate-risk prostate cancer in the setting of short-course neoadjuvant androgen deprivation?

Can we avoid dose escalation for intermediate-risk prostate cancer in the setting of short-course neoadjuvant androgen deprivation?

Thomas P Shakespeare,1,2 Shea W Wilcox,1 Noel J Aherne1,2 1Department of Radiation Oncology, North Coast Cancer Institute, 2Faculty of Medicine, Rural Clinical School, The University of New South Wales, Coffs Harbour, New South Wales, Australia Background: Both dose-escalated external beam radioth...

Full description

Bibliographic Details
Main Authors: Shakespeare TP, Wilcox SW, Aherne NJ
Format: Article
Language:English
Published: Dove Medical Press 2016-03-01
Series:OncoTargets and Therapy
Subjects:
radiotherapy
IMRT
dose
dose-escalation
dose-de-escalation
androgen deprivation therapy
prostate cancer
Online Access:https://www.dovepress.com/can-we-avoid-dose-escalation-for-intermediate-risk-prostate-cancer-in--peer-reviewed-article-OTT

Internet

https://www.dovepress.com/can-we-avoid-dose-escalation-for-intermediate-risk-prostate-cancer-in--peer-reviewed-article-OTT

Similar Items